Literature DB >> 10939571

Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype.

A M Fagan1, L H Younkin, J C Morris, J D Fryer, T G Cole, S G Younkin, D M Holtzman.   

Abstract

The epsilon4 allele of apolipoprotein E (ApoE) is a risk factor for Alzheimer's disease (AD). ApoE, which is important for lipid metabolism, is also a major constituent of cerebrospinal fluid (CSF) lipoproteins (LPs). Although ApoE in the CSF is derived from the central nervous system, the relation between LP metabolism in plasma and CSF is not clear. Soluble amyloid-beta (Abeta) protein may normally be associated with CSF LPs. It is converted in AD to a fibrillar form in brain parenchyma. ApoE and CSF LPs may regulate this process. The purpose of this study was to characterize CSF LPs from healthy, cognitively normal, fasted, elderly individuals at different risk for AD based on ApoE genotype. Lipid composition of CSF LPs did not differ with ApoE genotype. Interestingly, plasma and CSF high-density lipoprotein (HDL) cholesterol and apolipoprotein AI (ApoAI) levels were correlated. Importantly, as assessed by size-exclusion chromatography, Abeta in CSF coeluted in fractions containing LPs and was influenced by ApoE genotype: E4-positive subjects displayed significant elevations in Abeta40/Abeta42 ratios. These results suggest that plasma ApoAI/HDL levels can influence CSF ApoAI/HDL levels and that interactions between Abeta and central nervous system LPs may reflect changes in brain Abeta metabolism before the onset of clinical disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10939571

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  43 in total

1.  ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis.

Authors:  Anne M Fagan; Erin Christopher; Jennie W Taylor; Maia Parsadanian; Michael Spinner; Melanie Watson; John D Fryer; Suzanne Wahrle; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

2.  Preferential interactions between ApoE-containing lipoproteins and Aβ revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift.

Authors:  Mary Jo LaDu; Gregory W Munson; Lisa Jungbauer; Godfrey S Getz; Catherine A Reardon; Leon M Tai; Chunjiang Yu
Journal:  Biochim Biophys Acta       Date:  2011-11-23

3.  Plasma biomarkers for neuronal ceroid lipofuscinosis.

Authors:  Samantha L Hersrud; Ryan D Geraets; Krystal L Weber; Chun-Hung Chan; David A Pearce
Journal:  FEBS J       Date:  2015-12-17       Impact factor: 5.542

4.  Invited commentary: lipoproteins and dementia - is it the apolipoprotein A-I?

Authors:  Nikolaos Scarmeas
Journal:  Am J Epidemiol       Date:  2007-02-13       Impact factor: 4.897

5.  The Extensible Neuroimaging Archive Toolkit: an informatics platform for managing, exploring, and sharing neuroimaging data.

Authors:  Daniel S Marcus; Timothy R Olsen; Mohana Ramaratnam; Randy L Buckner
Journal:  Neuroinformatics       Date:  2007

6.  Soluble amyloid-β levels and late-life depression.

Authors:  Ricardo S Osorio; Tyler Gumb; Nunzio Pomara
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

7.  Apolipoprotein E Inhibits Cerebrovascular Pericyte Mobility through a RhoA Protein-mediated Pathway.

Authors:  Caroline S Casey; Yuka Atagi; Yu Yamazaki; Mitsuru Shinohara; Masaya Tachibana; Yuan Fu; Guojun Bu; Takahisa Kanekiyo
Journal:  J Biol Chem       Date:  2015-04-22       Impact factor: 5.157

8.  Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.

Authors:  Nigel J Cairns; Milos D Ikonomovic; Tammie Benzinger; Martha Storandt; Anne M Fagan; Aarti R Shah; Lisa Taylor Reinwald; Deborah Carter; Angela Felton; David M Holtzman; Mark A Mintun; William E Klunk; John C Morris
Journal:  Arch Neurol       Date:  2009-12

9.  Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls.

Authors:  Thomas J Esparza; Hanzhi Zhao; John R Cirrito; Nigel J Cairns; Randall J Bateman; David M Holtzman; David L Brody
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

Review 10.  The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer's disease.

Authors:  Xianlin Han
Journal:  Mol Neurobiol       Date:  2010-01-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.